Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.
Overall, the tariffs are expected to cost the average U.S. household an additional $2,400 — impacting things like food, school supplies, clothing and cars — and erode disposable income. For American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback